Can Adagio’s Adintrevimab Hold Up Against Omicron BA.2?

 
• By Alaric DeArment

The company will seek an EUA for the COVID-19 antibody after trial data indicated efficacy against Omicron, but studies have called into question its potency against the rapidly expanding subvariant.

Adagio announced Phase II/III data for adintrevimab in COVID-19 prevention and treatment • Source: Alamy

More from COVID-19

More from Scrip